论文部分内容阅读
本文分析了甲亢~（131）Ⅰ治疗前后血清TGA、TMA测定结果与甲减发生的关系。77例前后对照资料表明:在治疗前抗体阳性组和阴性组中甲减发生率分别为12.5％及14.2％,甲减组与非甲减组抗体阳性率分别为70.0％及73.1％,均无显著性差异;~（131）Ⅰ治疗后抗体阳性组和阴性组中甲减发生率分别为6.7％及17.0％,甲减组与非甲减组抗体阳性率分别为20.0％及41.8％,显然抗体阳性对于甲减的发生无影响;同时发现~（131）Ⅰ治疗后46.4％的患者TGA、TMA转阴,而疗前为阴性者疗后无1例出现阳性。427例疗后患者抗体测定结果也与甲亢疗效无关。据此,我们认为甲亢患者TGA、TMA阳性不能作为禁忌~(131)Ⅰ治疗的指征。
This article analyzes the relationship between the results of TGA and TMA before and after hyperthyroidism ~ (131) Ⅰ treatment and hypothyroidism. The data of 77 cases before and after treatment showed that the incidence of hypothyroidism was 12.5% and 14.2% respectively in the positive and negative groups before treatment, and the positive rates of hypothyroidism and non-hypothyroidism were 70.0% and 73.1% respectively The positive rates of Hypothyroidism (Hypothyroidism) were 6.7% and 17.0% in the positive and negative groups after ~ (131) Ⅰ treatment, respectively, and the positive rates of Hypothyroidism and non-hypothyroidism were 20.0% and 41.8% respectively Antibody positive had no effect on the occurrence of hypothyroidism. At the same time, 46.4% of patients treated with ~ (131) Ⅰ had negative TGA and TMA, but none of them were positive after treatment. 427 patients after antibody antibody test results have nothing to do with hyperthyroidism. Accordingly, we believe that TGA, TMA-positive patients with hyperthyroidism can not be used as an indication of taboo ~ (131) Ⅰ treatment.